GlassScriptPhysician profile
Johnny Cl Wong
NPI 1922024769
$14,352.11
in general payments reported to CMS, 2019-2025
39 companies · $2,908 in 2025
The $2,908 reported for 2025 was more than what 82% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,166 · 2020: $1,336 · 2021: $2,387 · 2022: $2,181 · 2023: $1,961 · 2024: $2,413 · 2025: $2,908.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,062 · Education: $219.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,062.41 |
| Education | $219.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,494.12 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Glaxosmithkline, LLC. | $2,223.62 | 2019-2025 | Trelegy Ellipta, Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,571.20 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Genzyme Corporation | $945.60 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $804.61 | 2019-2025 | |
| Grifols USA, LLC | $802.80 | 2019-2025 | Prolastin-C Liquid, Xembify |
| Regeneron Healthcare Solutions, INC. | $672.46 | 2019-2025 | Dupixent |
| Insmed, INC. | $578.35 | 2020-2025 | Arikayce, Brinsupri |
| Mylan Specialty L.P. | $394.58 | 2019-2024 | Yupelri |
| Mallinckrodt Hospital Products INC. | $372.30 | 2020-2025 | Acthar |
| Genentech USA, INC. | $339.41 | 2019-2025 | Xolair |
| United Therapeutics Corporation | $305.10 | 2021-2025 | Tyvaso, Tyvaso |
| Takeda Pharmaceuticals U.S.A., INC. | $283.68 | 2020-2025 | Glassia, Cuvitru |
| Paratek Pharmaceuticals, INC. | $260.70 | 2021-2023 | Nuzyra |
| Verona Pharma, INC. | $209.24 | 2025 | Ohtuvayre |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $189.08 | 2021-2025 | |
| Amgen INC. | $176.95 | 2024-2025 | Tezspire |
| Viatris Specialty LLC | $157.93 | 2025 | Yupelri |
| Baxter Healthcare | $157.30 | 2022-2025 | Hillrom - Monarch Airway Clearance System |
| Sanofi-Aventis U.S. LLC | $136.94 | 2022-2024 | |
| Actelion Pharmaceuticals US, INC. | $134.54 | 2024 | Opsumit, Uptravi |
| Electromed, INC. | $132.74 | 2021-2025 | Smartvest |
| Pulmonx Corporation | $125.02 | 2023-2025 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Pharming Healthcare, INC. | $123.94 | 2023-2024 | Ruconest |
| Sunovion Pharmaceuticals INC. | $77.93 | 2019-2021 | |
| Advanced Respiratory, INC | $77.70 | 2019-2021 | |
| Inogen, INC. | $74.68 | 2022-2025 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Vifor Pharma, INC. | $71.06 | 2024-2025 | Zemaira, Veltassa |
| Gilead Sciences, INC. | $70.46 | 2022 | |
| Abbvie INC. | $62.50 | 2023-2024 | Avycaz |
| Philips North America LLC | $60.82 | 2020-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Nabriva Therapeutics, Plc | $54.04 | 2021 | |
| Merck Sharp & Dohme LLC | $51.14 | 2019-2023 | |
| Teva Pharmaceuticals USA, INC. | $46.90 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $33.60 | 2021 | |
| Circassia INC. | $29.33 | 2019-2020 | |
| Ethicon INC. | $21.67 | 2025 | Monarch Platform |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $14.15 | 2019 | |
| Hikma Pharmaceuticals USA | $13.92 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Johnny Wong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.